Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series

Breast Cancer Research and Treatment

Volumn 148, Issue 1, 2014, Pages 73-80

  Di Lauro, Luigi ^a   Vici, Patrizia ^a   Barba, Maddalena ^a   Pizzuti, Laura ^a   Sergi, Domenico ^a   Rinaldi, Massimo ^a   Di Benedetto, Anna ^a   Sperduti, Isabella ^a   Shaaban, Abeer M ^b   Speirs, Valerie ^c   Mottolese, Marcella ^a   De Maria, Ruggero ^a   Maugeri Saccà, Marcello ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Androgen receptor; Antiandrogens; Cyproterone acetate; GnRH analogs; Metastatic male breast cancer

Indexed keywords

AMINOGLUTETHIMIDE; ANDROGEN RECEPTOR; BUSERELIN; CYCLOPHOSPHAMIDE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; FLUOROURACIL; FOSFESTROL; GOSERELIN; MEDROXYPROGESTERONE ACETATE; METHOTREXATE; MITOMYCIN; PREDNISONE; TAMOXIFEN; TESTOLACTONE; VINCRISTINE; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AR PROTEIN, HUMAN;

ADULT; AGED; ANTIANDROGEN THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; HUMAN; MALE; MALE BREAST CANCER; METASTASIS; MIDDLE AGED; MONOTHERAPY; ORCHIECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; BIOSYNTHESIS; BREAST NEOPLASMS, MALE; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MORTALITY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS, MALE; CYPROTERONE ACETATE; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RECEPTORS, ANDROGEN; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84922074874     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3138-9     Document Type: Article

References (25)

1. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN (2004) Breast carcinoma in men: a population-based study. Cancer 101:51–57
2. Anderson WF, Jatoi I, Tse J, Rosenberg PS (2010) Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol 28:232–239
3. White J, Kearins O, Dodwell D, Horgan K, Hanby AM, Speirs V (2011) Male breast carcinoma: increased awareness needed. Breast Cancer Res 13:219
4. Lopez M, Di Lauro L, Lazzaro B, Papaldo P (1985) Hormonal treatment of disseminated male breast cancer. Oncology 42:345–349
5. Eggemann H, Ignatov A, Smith BJ, Altmann U, von Minckwitz G, Röhl FW, Jahn M, Costa SD (2013) Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat 137:465–470
6. Doyen J, Italiano A, Largillier R, Ferrero JM, Fontana X, Thyss A (2010) Aromatase inhibition in male breast cancer patients: biological and clinical implications. Ann Oncol 21:1243–1245
7. Zagouri F, Sergentanis TN, Koutoulidis V, Sparber C, Steger GG, Dubsky P, Zografos GC, Psaltopoulou T, Gnant M, Dimopoulos MA et al (2013) Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. Br J Cancer 108:2259–2263
8. Di Lauro L, Vici P, Del Medico P, Laudadio L, Tomao S, Giannarelli D, Pizzuti L, Sergi D, Barba M, Maugeri-Saccà M (2013) Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. Breast Cancer Res Treat 141:119–123
9. Zagouri F, Sergentanis TN, Chrysikos D, Zografos E, Rudas M, Steger G, Zografos G, Bartsch R (2013) Fulvestrant and male breast cancer: a case series. Ann Oncol 24:265–266
10. Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, Bartlett JM, Gelmon K, Nahleh Z, Bergh J et al (2010) Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 28:2114–2122
11. Johansson I, Nilsson C, Berglund P, Lauss M, Ringnér M, Olsson H, Luts L, Sim E, Thorstensson S, Fjällskog ML et al (2012) Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies Nacetyltransferase-1 (NAT1) as a novel prognostic biomarker. Breast Cancer Res 14:R31
12. Callari M, Cappelletti V, De Cecco L, Musella V, Miodini P, Veneroni S, Gariboldi M, Pierotti MA, Daidone MG (2011) Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Res Treat 127:601–610
13. Shaaban AM, Ball GR, Brannan RA, Cserni G, Di Benedetto A, Dent J, Fulford L, Honarpisheh H, Jordan L, Jones JL et al (2012) A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Res Treat 133:949–958
14. Lopez M (1985) Cyproterone acetate in the treatment of metastatic cancer of the male breast. Cancer 55:2334–2336
15. Lopez M, Natali M, Di Lauro L, Vici P, Pignatti F, Carpano S (1993) Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer. Cancer 72:502–505
16. Wenhui Z, Shuo L, Dabei T, Ying P, Zhipeng W, Lei Z, Xiaohui H, Jingshu G, Hongtao S, Qingyuan Z (2014) Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to Tamoxifen treatment. Eur J Endocrinol 171(4):527–533
17. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD (1977) Assessment of response to therapy in advanced breast cancer. Cancer 39:1289–1294
18. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214
19. Doberauer C, Niederle N, Schmidt CG (1988) Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide. Cancer 62:474–478
20. Maugeri-Saccà M, Barba M, Vici P, Pizzuti L, Sergi D, De Maria R, Di Lauro L (2014) Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations. Breast Cancer Res Treat. doi:10.1007/s10549-014-3087-3
21. Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I (2002) Estradiol in elderly men. Aging Male 5:98–102
22. Lopez M, Di Lauro L, Papaldo P, Lazzaro B (1985) Chemotherapy in metastatic male breast cancer. Oncology 42:205–209
23. Giordano SH, Hortobagyi GN (2006) Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol 24:e42–e43
24. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005
25. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197